Sovremennye rekomendatsii po farmakoterapii ostrogo epizoda bipolyarnoy depressii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Optimal pharmacotherapy of bipolar depression (BD) still remains a matter of debate. The article presents the recommendations of various countries on the choice of therapeutic tactics in the treatment of BD episode. The analysis of the contradictions in the international recommendations was performed; it is emphasized that despite the conflicting views of experts on the appropriateness of antidepressants for the treatment of BD, this group of drugs is still the most widely used in real medical practice.

Full Text

Restricted Access

About the authors

A. V Ushkalova

E. A Ushkalova

Email: eushk@yandex.ru

References

  1. Lloyd L.C., Giaroli G., Taylor D., Tracy D.K. Bipolar depression: clinically missed, pharmacologically mismanaged. Ther. Adv. Psychopharmacol. 2011; 1(5): 153-62.
  2. Judd L.L., Akiskal H.S., Schettler P.J., Coryell W., Endicott J., Maser J.D., Solomon D.A., Leon A.C., Keller M.B. A prospective investigationof the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry. 2003; 60: 261-69.
  3. Vieta E., Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013; 27(7): 515-22.
  4. Kupka R.W., Altshuler L.L., Nolen W.A., Suppes T., Luckenbaugh D.A., Leverich G.S., Frye M.A., Keck P.E. Jr., McElroy S.L., Grunze H., Post R.M. Three times more days depressed than manic orhypomanic in both bipolar I and bipolar II disorder. Bipolar. Disord. 2007; 9: 531-35.
  5. Michalak E.E., Murray G., Young A.H., Lam R.W. Burden of bipolar depression: impact of disorder and medications on quality of life. CNS Drugs. 2008; 22(5): 389-406.
  6. Weisenbach S.L., Marshall D., Weldon A.L., Ryan K.A., Vederman A.C., Kamali M., Zubieta J.K., McInnis M.G., Langenecker S.A. The double burden of age and disease on cognition and quality of life in bipolar disorder. Int. J. Geriatr. Psychiatry. 2014; 29(9): 952-61.
  7. Gutie'rrez-Rojas L., Gurpegui M., Ayuso-Mateos J.L., Gutierrez-Ariza J.A., Ruiz-Veguilla M., Jurado D. Quality of life in bipolar disorder patients: a comparison with a general population sample. Bipolar Disord. 2008; 10(5): 625-34.
  8. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Leon A.C., Solomon D.A., Coryell W., Maser J.D., Keller M.B. Psychosocial disability in the course of bipolar I and II disorders. Arch. Gen. Psychiatry. 2005; 62(12): 1322-30.
  9. Altshuler L.L., Post R.M., Black D.O., Keck P.E. Jr., Nolen W.A., Frye M.A., Suppes T., Grunze H., Kupka R.W., Leverich G.S., McElroy S.L., Walden J., Mintz J. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J. Clin. Psychiatry. 2006; 67(10): 1551-60.
  10. Chen L., Liu Y.H., Zheng Q.W., Xiang Y.T., Duan Y.P., Yang F.D., Wang G., Fang Y.R., Lu Z., Yang H.C., Hu J., Chen Z.Y., Huang Y., Sun J., Wang X.P., Li H.C., Zhang J.B., Chen D.F., Si T.M. Suicide risk in major affective disorder: Results from a national survey in China. J. Affect Disord. 2014; 155: 174-79.
  11. Bowden C.L. A different depression: clinical distinctions between bipolar and unipolar depression. J. Affect Disord. 2005; 84: 117-25.
  12. Tondo L., Isacsson G., Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003; 17: 491-511.
  13. Malhi G.S., Adams D., Berk M. Medicating mood with maintenancein mind: bipolar depression pharmacotherapy. Bipolar. Disord. 2009; 11(Suppl. 2): 55-76.
  14. Ghaemi S.N., Boiman E.E., Goodwin F.K. Diagnosing bipolardisorder and the effect of antidepressants: a naturalistic study. J. Clin. Psychiatry. 2000; 61: 804-08.
  15. Altshuler L.L., Post R.M., Leverich G.S., Mikalauskas K., Rosoff A., Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am. J. Psychiatry. 1995; 152(8): 1130-38.
  16. Bauer M., Ritter P., Grunze H., Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar. Disord. 2012: 14(Suppl. 2): 37-50.
  17. Grunze H., Vieta E., Goodwin G., Bowden C., Licht R.W., Moller H.J., Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2009 on the treatment of bipolar depression. World J. Biol. Psychiatry. 2009; 10(2): 85-116.
  18. Yatham L.N., Kennedy S.H., Parikh S.V., Schaffer A., Beaulieu S., Alda M., O'Donovan C., Macqueen G., McIntyre R.S., Sharma V., Ravindran A., Young L.T., Milev R., Bond D.J., Frey B.N., Goldstein B.I., Lafer B., Birmaher B., Ha K., Nolen W.A., Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar. Disord. 2013; 15(1): 1-44.
  19. Goodwin G.M. and Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition recommendations from the British Association for Psychopharmacology. J. Psychopharmacol.2009; 23: 346-88.
  20. Kasper S., Calabrese J.R., Johnson G., Tajima O., Vieta E. International Consensus Group on the Evidence-based Pharmacological Treatment of Bipolar I and II Depression. J. Clin. Psychiatry. 2008; 69(10): 1632-46.
  21. NICE Clinical Guidelines. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence, 2009.
  22. Vieta E., Murru A., Pueyo M.J. Guia sobre el maneig del tratorn bipolar a Catalunya. Barcelona: Age'ncia d'Informacio', Avaluacio i Qualitat en Salut. Servei Catala' de la Salut. Departament de Salut. Generalitat de Catalunya, 2011.
  23. Paterniti S., Bisserbe J.C. Pharmacotherapy for bipolar disorder and concordance with treatment guidelines: survey of a general population sample referred to a tertiary care service. BMC Psychiatry. 2013; 13: 211.
  24. Baldessarini R.J., Henk H.J., Sklar A.R., Chang J., Leahy L.F. Use of psychotropic medicines in bipolar disorder patients in the United States: combinations and adherence. American Psychiatric Association. 2008; 59: 1175-83.
  25. Greil W., Haberle A., Haueis P., Grohmann R., Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J. Affect Disord. 2012; 136(3): 534-42.
  26. Sidor M.M., MacQueen G.M. An Update on Antidepressant Use in Bipolar Depression. Curr. Psychiatry Rep. 2012 Dec; 14(6): 696-704.
  27. Gijsman H.J., Geddes J.R., Rendell J.M., Nolen W.A., Goodwin G.M. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry. 2004; 161(9): 1537-47.
  28. Sidor M.M., Macqueen G.M. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J. Clin. Psychiatry. 2010; 72: 156-67.
  29. Tondo L., Vazquez G., Baldessarini R.J. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr. Scand. 2010; 121(6): 404-14.
  30. Nivoli A.M., Colom F., Murru A., Acchiarotti I., Castro-Loli P., Gonzalez-Pinto A., Fountoulakis K.N., Vieta E. New treatment guidelines for acute bipolar depression: a systematic review. J. Affect Disord. 2011; 129(1-3): 14-26.
  31. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet. 2013; 381(9878): 1672-82.
  32. Martinotti G., Sepede G., Signorelli M., Aguglia E., Di Giannantonio M. Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review. Expert. Opin. Pharmacother. 2013; 14(8): 1065-75.
  33. McElroy S.L.,Young A.H., Carlsson A., Olausson B., Nordenhem A., Paulsson B., Brecher M. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and paroxetine in adults with bipolar deprssion (EMBOLDEN II).Bipolar. Disord. 2008; 10(Suppl. 1): 59.
  34. Amsterdam J.D., Wang G., Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr. Scand. 2010; 121(3): 201-08.
  35. Amsterdam J.D., Wang C.H., Shwarz M., Shults J. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trialJ Affect Disord. 2009; 112(1-3): 219-30.
  36. Valenti' M., Pacchiarotti I., Rosa A.R., Bonnin C.M., Popovic D., Nivoli A.M., Murru A., Grande I., Colom F., Vieta E. Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar. Disord. 2011; 13(2): 145-54.
  37. Rihmer Z. [Antidepressants, depression and suicide]. Neuropsychopharmacol Hung. 2013; 15(3): 157-64.
  38. Young L.T., Joffe R.T., Robb J.C., MacQueen G.M., Marriott M., Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry. 2000; 157(1): 124-26.
  39. Schaffer A., Zuker P., Levitt A. Randomized, double blind pilot trial comparing lamotrigi-ne versus citalopram for the treatment of bipolar depression. J. Affect Disord. 2006; 96(1-2): 95-9.
  40. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., Friedman E.S., Bowden C.L., Fossey M.D., Ostacher M.J., Ketter T.A., Patel J., Hauser P., Rapport D., Martinez J.M., Allen M.H., Miklowitz D.J., Otto M.W., Dennehy E.B., Thase M.E. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 2007; 356(17): 1711-22.
  41. Nemeroff C.B., Evans D.L., Gyulai L., Sachs G.S., Bowden C.L., Gergel I.P., Oakes R., Pitts C.D. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry. 2001; 158(6): 906-12.
  42. van der Loos M.L., Mulder P., Hartong E.G., Hartong E.G., Blom M.B., Vergouwen A.C., van Noorden M.S., Timmermans M.A., Vieta E., Nolen W.A. LamLit Study Group. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr. Scand.2010; 122(3): 246-54.
  43. American Psychiatric Association. Practice guideline for the treatmentof patients with bipolar disorder (revision). Am. J. Psychiatry.2002; 159(4 Suppl.): 1-50.
  44. Bauer M. [A new evidence and consensus-based German guidelines for diagnosis and treatment of bipolar disorders]. Nervenarzt. 2012; 83(5): 564-67.
  45. Pfennig A., Bschor T., Falkai P., Bauer M. The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline. Dtsch Arztebl Int. 2013; 110(6): 92-100.
  46. Goodwin F.K., Murphy D.L., Dunner D.L., Bunney W.E. Jr. Lithium response in unipolar versus bipolar depression. Am J Psychiatry.1972; 129(1): 44-7.
  47. Mendels J. Lithium in the acute treatment of depressive states in Lithium research and therapy. Edited by Johnson F.N. London: Academic Press; 1975.
  48. Gelenberg A.J., Kane J.M., Keller M.B., Lavori P., Rosenbaum J.F., Cole K., Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N. Engl. J. Med. 1989; 321(22): 1489-93.
  49. Keller M.B., Lavori P.W., Kane J.M., Gelenberg A.J., Rosenbaum J.F., Walzer E.A., Baker L.A. Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch. Gen. Psychiatry. 1992; 49(5): 371-76.
  50. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent metaanalysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry. 2009; 194: 4-9.
  51. Smith L.A., Cornelius V.R., Azorin J.M., Perugi G., Vieta E., Young A.H., Bowden C.L. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J. Affect Disord. 2010; 122(1-2): 1-9.
  52. Bond D.J., Lam R.W., Yatham L.N. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2010; 124(3): 228-34.
  53. Post R.M., Ketter T.A., Denicoff K., Pazzaglia P.J., Leverich G.S., Marangell L.B., Callahan A.M., George M.S., Frye M.A. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl). 1996; 128(2): 115-29.
  54. Fountoulakis K.N., Kasper S., Andreassen O., Blier P., Okasha A., Severus E., Versiani M., Tandon R. Muller H.J., Vieta E. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur. Arch. Psychiatry Clin. Neurosci. 2012; 262(Suppl. 1): 1-48.
  55. Cerullo M.A., Strakowski S.M. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectr. 2013; 18(4): 199-208.
  56. Taylor D.M., Cornelius V., Smith L., Young A.H. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr. Scand. 2014; 130(6): 452-69.
  57. Selle V., Schalkwijk S., Vzquez G.H., Baldessarini R.J. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014; 47(2): 43-52.
  58. Lehman A.F., Steinwachs D.M. Translating research into practice: the schizophrenia patient outcomes research team (port) treatment recommendations. Schizophr Bull. 1998; 24: 1-10.
  59. Fountoulakis K.N., Vieta E., Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. J. Affect Disord. 201; 133(3): 361-70.
  60. Lombardo I., Sachs G., Kolluri S., Kremer C., Yang R. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol. 2012; 32(4): 470-78.
  61. Sachs G.S., Ice K.S., Chappell P.B., et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2001; 72: 1413-22.
  62. Merikangas K.R., Akiskal H.S., Angst J., Greenberg P.E., Hirschfeld R.M., Petukhova M., Kessler R.C. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry. 2007; 64(9): 543-52.
  63. Bond D.J., Noronha M.M., Kauer-Santm, Lam R.W., Yatham L.N. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J. Clin. Psychiatry. 2008; 69(10): 1589-601.
  64. Swartz H.A., Thase M.E. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J. Clin. Psychiatry. 2011; 72: 356-66.
  65. Suppes T., Marangell L.B., Bernstein I.H., Kelly D.I., Fischer E.G., Zboyan H.A., Snow D.E., Martinez M., Al Jurdi R., Shivakumar G., Sureddi S., Gonzalez R. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J. Affect Disord. 2008; 111(2-3): 334-43.
  66. Wang P.W., Nowakowska C., Chandler R.A., Hill S.J., Nam J.Y., Culver J.L., Keller K.L., Ketter T.A. Divalproex extended-release in acute bipolar II depression. J. Affect Disord. 2010; 124(1-2): 170-73.
  67. Winsberg M.E., DeGolia S.G., Strong C.M., Ketter T.A. Divalproex therapy in medication-naive and mood-stabilizernaive bipolar II depression. J. Affect Disord. 2001; 67(1-3): 207-12.
  68. Amsterdam J.D., Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J. Clin. Psychopharmacol. 2010; 30: 306-11.
  69. Malhi G.S., Bargh D.M., Cashman E., Frye M.A., Gitlin M. The clinical management of bipolar disorder complexity using a stratified model. Bipolar. Disord. 2012: 14(Suppl. 2): 66-89.
  70. Jann M.W. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. Am. Health Drug Benefits. 2014; 7(9): 489-99.
  71. Kemp D.E. Managing the side effects associated with commonly used treatments for bipolar depression. J. Affect Disord. 2014; 169S1: S34-S44.
  72. Hasnain M., Vieweg W.V. Weight considerations in psychotropic drug prescribing and switching. Postgrad Med. 2013; 125(5): 117-29.
  73. Fiorillo A., Del Vecchio V., Luciano M., Sampogna G., De Rosa C., Malangone C., Volpe U., Bardicchia F., Ciampini G., Crocamo C., Iapichino S., Lampis D., Moroni A., Orlandi E., Piselli M., Pompili E, Veltro F., Carra G., Maj M. Efficacy of psychoeducational family intervention for bipolar I disorder: A controlled, multicentric, real-world study. J. Affect Disord. 2014; 172C: 291-99.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies